Latest Drugwonks' Blog

Must see TV, eh?

  • 06.18.2008
According to PharmaTimes, CanWest Mediaworks, Canada’s largest newspaper publisher and owner of more than 30 television stations, is suing the federal government for not permitting direct-to-consumer advertising of prescription drugs because, it says, this breaches its freedom of expression under Canada’s Charter of Rights and Freedoms.

CanWest is arguing in the Ontario Superior Court that this prohibition, which is part of the Canadian Food and Drugs Act, places it at a competitive disadvantage to US newspaper and magazines which are sold on Canadian newsstands, because it prevents it from selling advertising space to pharmaceutical manufacturers. The company also points out that Canada does allow OTC medicines to be advertised directly to consumers, even though these products also carry risks.

The case will be heard this month.
On Monday the AMA House of Delegates soundly rejected the recommendations of The Council on Ethical and Judicial Affairs: Industry Support of Professional Education in Medicine. The report echoed the Macy Foundation Report's recommendation to remove all commercial support for medical education.

Earlier in the day the Reference Committee on Amendments to Constitution and Bylaws recommended the CEJA report “for referral" so that it will not be presented on the house floor for a vote.

Since the Reference Committee did not recommend “not adoption,” CEJA can revise and (improve) their report for presentation at a later meeting as soon as this time next year. However, given the strength of almost unanimous opposition to the recommendation, it’s not likely come back to the House of Delegates anytime soon.

At the reference committee hearing on Sunday only two speakers spoke in favor of adoption of the report; the current CEJA chairman, Mark Levine, MD, and one other physician( unaffiliated).

According to our roving correspondent, when Dr. Levine stood up at the microphone to present his committee’s report he told the Chairman of the reference committee, Dr. Raymond Christenson, that he wouldn’t take up much time given that all those behind him in line were in favor of the proposal -- at which the chairman commented, “Dr. Levine there is no one behind you, so take your time.”

What time is it when Dr. Levine can’t see his shadow? Time to toss in the towel.

One of the strongest, most consistent, and eloquent voices against the CEJA proposal was Dr. Tom Stossel, American Cancer Society Professor of Medicine at Harvard Medical School.

We recently visited with Tom in his Boston office. Here’s a link to the video podcast:

www.vimeo.com/1186974

Take your time Tom; we’re all behind you.

BigGovHealth.org

  • 06.16.2008
In our post-SiCKO, pre-election environment, the Center for Medicine in the Public Interest is launching a new program that takes a careful and candid look at just what you get via government-run (aka "Universal") healthcare.

We call our project BigGovHealth.org.

We're beginning our initiative with a short movie that, we believe, shows why Big Government healthcare is the wrong prescription for the United States.

Please join us for the Washington, DC premiere on June 23 , from 6:30 - 8:00PM, at the National Press Club.


We will be joined by Congressman John Shadegg, former Senator Don Nickles and other healthcare players (we've even gotten an RSVP from a presidential candidate).

The complete invitation, along with RSVP information, can be found at the top of this page

When it comes to healthcare reform, BigGovHealth.org is Cinéma-vérité.

Stipulating Bias

  • 06.13.2008

According to a new editorial in the Lancet, “From February to April this year, the European Commission (EC) held a public consultation on proposed legal changes that would allow pharmaceutical companies to provide information to patients about prescription-only drugs via all available media. The Commission's proposal states that the ban on direct-to-consumer advertising (DTCA) in Europe would remain. However, many critics rightly feel that allowing the industry to provide information to patients is effectively DTCA under a different name.”

Who are these critics?  What are the agendas?  Where does their funding come from?  On these questions the Lancet is silent.

The Lancet opines, “Patients' access to quality information is variable across the European Union's 27 member states and the Commission is right to want to address this inequality. But the pharmaceutical industry's obvious financial conflicts of interest mean that drug information provided by them is likely to be prone to bias.”

“Likely to be biased?”  On what do they base this rather strong statement?  Isn’t solid, unbiased information in the best interests of both sales and the public health? Isn’t there a more inherent “bias” by having payers control what information consumers get to see?  And in the EU, “payers” = “government.”

The editorial concludes, “Patients have a fundamental right to access good quality, objective information on medicines. The EC's final proposal, due out later this year, must empower patients and not the drug industry.”

Why not empower the drug industry to empower patients?  That’s what the pending EC directive is all about.

And as far as the Lancet stipulating bias, consider the words of Robert Benchley:

"Tell us your phobias, and we will tell you what you are afraid of."

While the media covers the Grassley stains and Stupak remarks oozing from Congress, Ray Woosley and the C-Path Institute with strong backing from Janet Woodcock at the FDA are remaking the drug development process, transforming it from a hit or miss method to a pathway for personalized medicine. Today C-Path announced a trans-atlantic agreement to use the same drug safety biomarker at the FDA and the EMEA, a historic first. And let's not forget that industry is collaborating, much to the consternation of DeLauro,Goozner, Mahar, Brownlee and pharmalot. Progress towards safer, more effective medicines using more reliable measures. Oh, the humanity.

Read more here

Have NICE Life

  • 06.12.2008
CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog